

**WEST**

[Help](#) [Logout](#) [Interrupt](#)

[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#) [Preferences](#)

**Search Results -**

Terms	Documents
15 not 14	57

**Database:** [US Patents Full-Text Database](#)

US Pre-Grant Publication Full-Text Database  
 JPO Abstracts Database  
 EPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

15 not 14

[Refine Search:](#)

[Clear](#)

**Search History**

**Today's Date:** 4/20/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	15 not 14	57	<u>L6</u>
USPT	lethal.clm. and gene.clm.	60	<u>L5</u>
USPT	lethal.clm. and essential.clm.	4	<u>L4</u>
USPT	pmeg same plasmid	4	<u>L3</u>
USPT	pmeg	42	<u>L2</u>
USPT	pmeg-104 or pmeg104 or (pmeg near2 104)	0	<u>L1</u>

**WEST** **Generate Collection**

L4: Entry 3 of 4

File: USPT

May 26, 1998

DOCUMENT-IDENTIFIER: US 5756305 A  
TITLE: Identification of essential survival genes

CLPR:

1. A method for identifying a strain carrying a conditional lethal mutation in a gene, the method comprising:

CLPR:  
2. A method of claim 1, further comprising after step (d), the step of selecting a strain carrying a recessive conditional lethal mutation.

CLPV:

(d) selecting a strain that survives step (a) but does not survive steps (b) and (c), thereby identifying a strain carrying a lethal mutation that is sensitive to the restrictive conditions and essential for survival of the strain.

**Engineering organisms for safety: what is necessary (query) - genetically engineered microorganism release in the environment; recombinant vaccine construction; a review (conference paper)**

AUTHOR: **Curtiss III R**

CORPORATE SOURCE: Department of Biology, Washington University, St. Louis, MO 63130, USA.

JOURNAL: Release GEMs (7-20) 1988

CODEN: 9999X

LANGUAGE: English

**ABSTRACT:** Methods for ensuring safety of recombinant microorganisms for containment or controlled release were reviewed. Topics discussed included historical background, goals in release of genetically engineered microorganisms, assessment of potential concerns, means by which the probability for survival and gene transmission is decreased, and use of genetically-modified microorganisms as safe live recombinant vaccines. The microorganism can be designed and constructed to achieve the established goals, and evaluated for its likelihood of causing harm. Physical containment and biological containment standards have been developed to reduce the probability of accidental release, and to reduce survival of strains outside the laboratory, respectively. No specific examples of possible harmful consequences in the use of a genetically engineered microorganism designed to achieve a beneficial purpose have yet been found. Strains discussed include *Escherichia coli*, *Bacillus thuringiensis*, *Pseudomonas fluorescens*, *Streptococcus mutans* and a *Salmonella typhimurium* vaccine strain. (91 ref)

**DESCRIPTORS:** genetically engineered microorganism safety, physical, biol. containment, release in environment, e.g. recombinant vaccine, review bacterium

SECTION: Microbiology-Genetics; Pharmaceuticals-Vaccines (A1,D4)